专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20130337559A1 HUMANIZED ANTI-TAG 72 CC49 FOR DIAGNOSIS AND THERAPY OF HUMAN TUMORS 有权
标题翻译：人类抗肿瘤药物CC49用于诊断和治疗人类肿瘤
公开(公告)号：US20130337559A1
公开(公告)日：2013-12-19
申请号：US13974476
申请日：2013-08-23
申请人： The Govt. of the U.S.A. as represented by the Secretary of the Dept. of Health & Human Services
发明人： Syed V.S. Kashmiri , Jeffrey Schlom , Eduardo Padlan
IPC分类号： C07K16/30
CPC分类号： C07K16/30 , A61K51/1045 , A61K2039/505 , C07K2317/24 , C07K2317/55 , C07K2317/622 , C07K2317/92
摘要： The present disclosure provides humanized CC49 monoclonal antibodies that bind TAG-72 with high binding affinity and that are minimally immunogenic. In one embodiment, a humanized CC49 antibody includes a non-conservative amino acid substitution in a light chain complementarity determining region 3 of the CC49 antibody. In a further embodiment, the humanized CC49 antibody includes a non-conservative substitution of a first residue in a light chain complementarity determining region 3 and a substitution of a second residue in a complementarity determining region of the humanized CC49 antibody. In several of the embodiments, methods are disclosed for the use of a humanized CC49 antibody.
摘要翻译：本公开提供以高结合亲和力结合TAG-72并且是免疫原性最小的人源化CC49单克隆抗体。在一个实施方案中，人源化CC49抗体包括CC49抗体的轻链互补决定区3中的非保守氨基酸取代。在另一个实施方案中，人源化CC49抗体包括轻链互补决定区3中的第一残基的非保守取代和人源化CC49抗体的互补决定区的第二残基的取代。在几个实施方案中，公开了使用人源化CC49抗体的方法。

2. 发明申请

US20110183324A1 TUMOR SUPPRESSOR GENE P33ING2 失效
标题翻译：肿瘤抑制基因P33ING2
公开(公告)号：US20110183324A1
公开(公告)日：2011-07-28
申请号：US13079743
申请日：2011-04-04
申请人： Curtis C. Harris , Makoto Nagashima
发明人： Curtis C. Harris , Makoto Nagashima
IPC分类号： C12Q1/68 , C12Q1/02 , C12N5/00 , G01N33/53
CPC分类号： C07H21/02 , C07H21/04 , C07K14/4703
摘要： The invention provides isolated nucleic acid and amino acid sequences of novel human tumor suppressors, antibodies to such tumor suppressors, methods of detecting such nucleic acids and proteins, methods of screening for modulators of tumor suppressors, and methods of diagnosing and treating tumors with such nucleic acids and proteins.
摘要翻译：本发明提供了新型人肿瘤抑制基因的分离的核酸和氨基酸序列，这种肿瘤抑制基因的抗体，检测这种核酸和蛋白质的方法，筛选肿瘤抑制因子调节剂的方法，以及用这种核酸诊断和治疗肿瘤的方法酸和蛋白质。

3. 发明申请

US20080279880A1 PEPTIDE VACCINES AGAINST GROUP A STREPTOCOCCI 有权
标题翻译：肽类疫苗对A组STREPTOCOCCI
公开(公告)号：US20080279880A1
公开(公告)日：2008-11-13
申请号：US12144461
申请日：2008-06-23
申请人： Bernard W. Beall , George M. Carlone , Jacquelyn S. Sampson , Edwin W. Ades
发明人： Bernard W. Beall , George M. Carlone , Jacquelyn S. Sampson , Edwin W. Ades
IPC分类号： A61K39/02 , A61K38/16 , A61K39/095 , A61K39/10 , A61K38/10
CPC分类号： A61K39/092 , A61K39/00 , C07K14/001 , C07K14/315 , C07K2319/00
摘要： This invention, in one aspect, relates to synthetic immunoreactive peptides. These peptides are approximately 20-25 amino acids in length which are portions of the N termini of the M proteins of the most prevalent United States (U.S.) Group A Streptococcus (GAS) serotypes. At least some of the synthetic peptides can be recognized by M type-specific antibodies and are capable of eliciting functional opsonic antibodies and/or anti-attachment antibodies without eliciting tissue cross-reactive antibodies. In another aspect, it relates to compositions or vaccines comprising these synthetic serotype-specific peptides, including polypeptides and proteins. The invention may also be isolated antibodies which are raised in response to the peptides, compositions or vaccines. The invention further relates to kits for using the peptides, compositions, or antibodies. In still further aspects, the invention also relates to methods for using the peptides, compositions, vaccines, or antibodies and methods for tailoring vaccines.
摘要翻译：本发明在一个方面涉及合成免疫反应肽。这些肽的长度约为20-25个氨基酸，它们是最流行的美国（A）链球菌（GAS）血清型的M蛋白的N末端的部分。至少一些合成肽可被M型特异性抗体识别，并且能够引发功能性调理抗体和/或抗附着抗体而不引发组织交叉反应性抗体。另一方面，本发明涉及包含这些合成血清型特异性肽（包括多肽和蛋白质）的组合物或疫苗。本发明还可以是响应于肽，组合物或疫苗引起的分离的抗体。本发明还涉及使用肽，组合物或抗体的试剂盒。在另外的方面，本发明还涉及使用肽，组合物，疫苗或抗体的方法和用于定制疫苗的方法。

4. 发明申请

US20080274994A1 CARDIAC MYOSIN LIGHT CHAIN KINASE AND METHODS OF USE 失效
公开(公告)号：US20080274994A1
公开(公告)日：2008-11-06
申请号：US12101812
申请日：2008-04-11
申请人： Neal D. Epstein , Shahin Hassanzadeh , Steven Winitsky , Julien S. Davis
发明人： Neal D. Epstein , Shahin Hassanzadeh , Steven Winitsky , Julien S. Davis
IPC分类号： A61K31/7088 , C12Q1/68 , C12N15/55 , C12N15/85 , C12N5/10 , C07K16/40 , A61P9/04
CPC分类号： C12N9/1205 , A01K2217/075 , A61K38/00 , C12N2799/026
摘要： The present disclosure provides a cDNA, protein sequence, and genomic structure of the human cardiac isoform of myosin light chain kinase (cMLCK), and describes mutations in the cMLCK gene that are associated with cardiac dysfunction. Methods are provided for identifying individuals who can harbor mutations in the cMLCK gene, or carry alleles that can predisposed them to cardiac dysfunction. Disclosed also is a significant role for cMLCK in modulating cardiac contractility. The cMLCK protein is shown herein to reduce the amplitude of stretch activation and increase the tension production, a property of muscle which has heretofore had an unknown role in cardiac contraction. Moreover, the cMLCK protein is shown to be regionally distributed in the heart, thereby having differential effects on contractility and stretch activation. Methods herein are provided to exploit this effect of cMLCK, to treat individuals who have or are prone to cardiac dysfunction. In addition, methods are provided to identify agents that modulate cMLCK activity, thereby having potential therapeutic importance in the treatment of cardiac dysfunction.
摘要翻译：本公开提供肌球蛋白轻链激酶（cMLCK）的人心脏同种型的cDNA，蛋白质序列和基因组结构，并描述与心脏功能障碍相关的cMLCK基因中的突变。提供了用于鉴定可以在cMLCK基因中存在突变的个体的携带方法，或携带可将它们倾向于心脏功能障碍的等位基因。还公开了cMLCK调节心脏收缩力的重要作用。本文显示了cMLCK蛋白以减少拉伸活化的幅度并增加张力产生，这是迄今在心脏收缩中未知作用的肌肉的性质。此外，cMLCK蛋白质显示在区域分布在心脏中，从而对收缩性和拉伸活化具有不同的影响。提供本文的方法以利用cMLCK的这种作用来治疗患有或易于发生心脏功能障碍的个体。此外，提供了用于鉴定调节cMLCK活性的药剂的方法，从而在治疗心脏功能障碍中具有潜在的治疗重要性。

5. 发明申请

US20060084051A1 Grid etcher 失效
标题翻译：网格蚀刻机
公开(公告)号：US20060084051A1
公开(公告)日：2006-04-20
申请号：US10967703
申请日：2004-10-14
申请人： Rea Ravin , James Sullivan , Daniel Hoeppner , David Munno , Ron McKay
发明人： Rea Ravin , James Sullivan , Daniel Hoeppner , David Munno , Ron McKay
IPC分类号： C12Q1/00 , H01L21/00
CPC分类号： C12M41/36 , G01N33/5029 , Y10S436/807 , Y10T83/0304
摘要： An apparatus and process for monitoring migratory cell proliferation with restricted migration on a substrate includes providing a substrate, coating the substrate with extracellular matrix, plating cells suspended in cell culture media on extracellular matrix, and placing intersecting channels across the extracellular matrix components by removing the extracellular matrix components from the channels to isolate islands of the extracellular matrix components on the substrate. When the cells are immersed with a fluid, migration of the cells is confined to the isolated islands of the extracellular matrix components, permitting long-term observation of a migratory population.
摘要翻译：用于通过限制性迁移在基质上监测迁移细胞增殖的装置和方法包括提供底物，用细胞外基质涂覆底物，将细胞悬浮于细胞培养基中的细胞悬浮于细胞外基质上，以及通过除去细胞外基质组分来自通道的细胞外基质组分以分离底物上细胞外基质组分的岛。当细胞浸入液体时，细胞的迁移被限制在细胞外基质组分的孤立岛上，从而允许长期观察迁移群体。

6. 发明申请

US20060057123A1 Method of inducing memory B cell development and terminal differentiation 有权
标题翻译：诱导记忆B细胞发育和终末分化的方法
公开(公告)号：US20060057123A1
公开(公告)日：2006-03-16
申请号：US11197221
申请日：2005-08-03
申请人： Catherine Ettinger , Peter Lipsky , Warren Leonard , Rosanne Spolski , Herbert Morse
发明人： Catherine Ettinger , Peter Lipsky , Warren Leonard , Rosanne Spolski , Herbert Morse
IPC分类号： A61K35/14 , C12N5/08
CPC分类号： G01N33/5052 , A61K35/17 , A61K38/20 , A61K2035/124 , A61K2039/5158 , C12N5/0635 , C12N2501/052 , C12N2501/23 , C12N2501/50 , C12N2501/52 , G01N2333/54
摘要： A method is disclosed herein for inducing differentiation of a B cell progenitor into a memory B cells and/or a plasma cell. The method includes contacting a population of cells including a mature B cell or a B cell progenitor with an effective amount of IL-21, and isolating memory B cells or plasma cells. In one embodiment, the B cell progenitor is an immature B cell. A method is also disclosed for enhancing an immune response. The method includes contacting a population of cells including a B cell progenitor with an effective amount of IL-21, and isolating memory B cells or plasma cells. The memory B cells and/or the plasma cell are then introduced into the subject to enhance the immune response. A method is also disclosed for treating a subject with a condition comprising a specific deficiency of at least one of memory B cells and plasma cells. A method is disclosed for identifying an agent with a physiological effect on one or more of a memory B cell and a plasma cell differentiation. A method is also disclosed for identifying agents that inhibit an activity of IL-21. Methods are also disclosed for inducing apoptosis of a B cell and for decreasing the number of B cells. A method is also described for producing a B cell hybridoma.
摘要翻译：本文公开了一种用于诱导B细胞祖细胞分化为记忆B细胞和/或浆细胞的方法。该方法包括使包含成熟B细胞或B细胞祖细胞的细胞群与有效量的IL-21接触，并分离记忆B细胞或浆细胞。在一个实施方案中，B细胞祖细胞是未成熟B细胞。还公开了一种用于增强免疫应答的方法。该方法包括使包含B细胞祖细胞的细胞群与有效量的IL-21接触，并分离记忆B细胞或浆细胞。然后将记忆B细胞和/或浆细胞引入受试者以增强免疫应答。还公开了一种用于治疗患有包含存储B细胞和浆细胞中的至少一种的特定缺陷的病症的受试者的方法。公开了用于鉴定对存储B细胞和浆细胞分化中的一种或多种具有生理作用的药剂的方法。还公开了用于鉴定抑制IL-21活性的试剂的方法。还公开了诱导B细胞凋亡和减少B细胞数量的方法。还描述了用于产生B细胞杂交瘤的方法。

7. 发明申请

US20030153047A1 AIB1, a novel steroid receptor co-activator 失效
公开(公告)号：US20030153047A1
公开(公告)日：2003-08-14
申请号：US10379616
申请日：2003-03-04
申请人： The Govt. of the U.S.A. as represented by the Secretary of the Dept. of Health & Human Services
发明人： Paul Meltzer , Jeffrey Trent
IPC分类号： C07K014/72 , C12P021/02 , C12N005/06
CPC分类号： C07K14/4705 , A01K2217/05 , A01K2217/075 , A61K38/00
摘要： The invention features a substantially pure DNA which includes a sequence encoding a novel steroid receptor co-activator which is overexpressed in breast cancer cells, diagnostic assays for steroid hormone-responsive cancers, and screening assays to identify compounds which inhibit an interaction of the co-activator with the steroid hormone.

8. 发明申请

US20120329066A1 FARNESYLTRANSFERASE INHIBITORS FOR TREATMENT OF LAMINOPATHIES, CELLULAR AGING AND ATHEROSCLEROSIS 失效
标题翻译：用于治疗肌肉瘤，细胞衰老和甲状腺功能亢进症的纤维素酶抑制剂
公开(公告)号：US20120329066A1
公开(公告)日：2012-12-27
申请号：US13567432
申请日：2012-08-06
申请人： Leslie B. Gordon , Francis S. Collins , Thomas Glover , Michael W. Glynn , Brian C. Capell , Adrienne D. Cox , Channing J. Der
发明人： Leslie B. Gordon , Francis S. Collins , Thomas Glover , Michael W. Glynn , Brian C. Capell , Adrienne D. Cox , Channing J. Der
IPC分类号： C12Q1/68
CPC分类号： A61K31/4545 , A61K31/4709 , A61K45/06 , C07K14/47 , C12Q1/6883 , C12Q1/6886 , C12Q2600/136 , C12Q2600/156 , G01N33/68 , G01N2333/91171 , G01N2500/04 , G01N2500/10
摘要： Although it can be farnesylated, mutant lamin A expressed in Hutchinson Gilford Progeria Syndrome cannot be defarnesylated; the characteristic mutation causes deletion of a cleavage site necessary for binding the protease ZMPSTE24 and effecting defarnesylation. The result is an aberrant farnesylated protein (“progerin”) that alters normal lamin A function as a dominant negative, and assumes its own aberrant function through its association with the nuclear membrane. Retention of farnesylation, and potentially other abnormal properties of progerin and other abnormal lamin gene protein products, produces disease. Farnesyltransferase inhibitors (FTIs) will inhibit formation of progerin, cause a decrease in lamin A protein, and/or an increase prelamin A protein. Decreasing the amount of aberrant protein improves cellular effects caused by and progerin expression. Similarly, treatment with FTIs should improve disease status in progeria and other laminopathies. In addition, elements of atherosclerosis and aging in non-laminopathy individuals will improve after treatment with FTIs.
摘要翻译：虽然它可以被法呢基化，但在Hutchinson Gilford Progeria综合征中表达的突变体蛋白A不能被脱乙酰化; 特征突变导致结合蛋白酶ZMPSTE24所需的切割位点的缺失并进行脱甲酰化。结果是异常的法呢基蛋白（progerin），其改变正常的lamin A功能作为显性阴性，并且通过与核膜的相关性而呈现其自身的异常功能。法尼基化的保留，以及progerin和其他异常的lamin基因蛋白产物的潜在其他异常性质产生疾病。法呢基转移酶抑制剂（FTIs）将抑制progerin的形成，导致lamin A蛋白降低，和/或增加prelamin A蛋白。减少异常蛋白质的量会改善由progerin表达引起的细胞效应。同样，FTIs治疗应改善progeria和其他层层病的疾病状况。此外，FTIs治疗后，动脉粥样硬化和非层状病变个体的老化因素将有所改善。

9. 发明申请

US20120252735A1 TREATMENT OF SKIN CONDITIONS BY DICKKOPF1 (DKK1) 有权
标题翻译： DICKKOPF1（DKK1）治疗皮肤病症
公开(公告)号：US20120252735A1
公开(公告)日：2012-10-04
申请号：US13492990
申请日：2012-06-11
申请人： Vincent Hearing , Yuji Yamaguchi , Thierry Passeron
发明人： Vincent Hearing , Yuji Yamaguchi , Thierry Passeron
IPC分类号： A61K38/17 , A61P17/00 , A61P17/02 , A61P35/00
CPC分类号： A61K38/1709 , A61K8/64 , A61Q7/02 , A61Q19/02
摘要： The present disclosure is generally related to methods of inducing non-palmoplantar skin to develop a palmoplantar phenotype, for example, methods for increasing skin thickness, decreasing skin pigmentation, and/or decreasing hair growth. In particular, disclosed herein are methods of using topical administration of DKK1 to increase skin thickness, decrease skin pigmentation, or reduce hair growth. Also disclosed are topical DKK1 compositions for inducing non-palmoplantar skin to develop a palmoplantar phenotype.
摘要翻译：本公开通常涉及诱导非掌跖皮肤发展掌跖表型的方法，例如增加皮肤厚度，减少皮肤色素沉着和/或减少毛发生长的方法。特别地，本文公开了使用局部施用DKK1以增加皮肤厚度，减少皮肤色素沉着或减少毛发生长的方法。还公开了用于诱导非掌跖皮肤发展掌跖表型的局部DKK1组合物。

10. 发明申请

US20110311586A1 Materials and methods for respiratory disease control in canines 有权
标题翻译：犬科呼吸系统疾病控制的材料与方法
公开(公告)号：US20110311586A1
公开(公告)日：2011-12-22
申请号：US13066651
申请日：2011-04-19
申请人： Patti C. Crawford , Paul J. Gibbs , Edward J. Dubovi , Ruben Omar Donis , Jacqueline Katz , Alexander I. Klimov , Nallakannu P. Lakshmanan , Melissa Anne Lum , Daniel Ghislena Emiel Goovaerts , Mark William Mellencamp , William L. Castleman , Nancy J. Cox
发明人： Patti C. Crawford , Paul J. Gibbs , Edward J. Dubovi , Ruben Omar Donis , Jacqueline Katz , Alexander I. Klimov , Nallakannu P. Lakshmanan , Melissa Anne Lum , Daniel Ghislena Emiel Goovaerts , Mark William Mellencamp , William L. Castleman , Nancy J. Cox
IPC分类号： A61K39/145 , C12N7/04 , C07H21/00 , A61P31/16 , C12N9/12 , C12N9/24 , A61P37/04 , C12N7/00 , C07K14/11
CPC分类号： A61K39/145 , A61K39/12 , A61K2039/5252 , A61K2039/53 , A61K2039/552 , A61K2039/55555 , A61K2039/55566 , C07K14/005 , C07K16/1018 , C12N7/00 , C12N15/86 , C12N2710/24043 , C12N2760/16121 , C12N2760/16122 , C12N2760/16134 , C12N2760/16151 , C12N2760/16171 , C12Q1/701 , G01N33/56983 , G01N2333/11
摘要： The subject invention pertains to isolated influenza virus that is capable of infecting canids and causing respiratory disease in the canid. The subject invention also pertains to compositions and methods for inducing an immune response against an influenza virus of the present invention. The subject invention also pertains to compositions and methods for identifying a virus of the invention and diagnosing infection of an animal with a virus of the invention.
摘要翻译：本发明涉及能够感染犬只并引起犬瘟呼吸系统疾病的分离的流感病毒。本发明还涉及用于诱导针对本发明的流感病毒的免疫应答的组合物和方法。本发明还涉及用于鉴定本发明的病毒并用本发明的病毒诊断动物的感染的组合物和方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式